Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOND-003: Cretostimogene Grenadenorepvec in BCG-unresponsive NMIBC
jRCT2043210017Phase 3Active, not recruiting
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Oct 2021
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
01
Overview
Phase 3, open-label trial of cretostimogene grenadenorepvec in bladder cancer and transitional cell carcinoma (TCC) (2 cohorts), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoints: Complete response rate (Cohort C) and High-grade event-free survival (Cohort P). Started Oct 2021; status: active, not recruiting.
02
Drugs
cretostimogene grenadenorepvec
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2043210017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2043210017.